Evofem Biosciences, Inc.
EVFM
$0.01
$0.00-8.54%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -671.65% | 191.80% | 33.66% | -232.05% | 119.88% |
| Total Depreciation and Amortization | -58.27% | -70.36% | -59.86% | 221.43% | 350.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 117.46% | -50.33% | -47.09% | 119.29% | -376.10% |
| Change in Net Operating Assets | 24.82% | -70.82% | 100.95% | -43,850.00% | 95.25% |
| Cash from Operations | 310.89% | 101.29% | 173.20% | -155.83% | 355.28% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -88.80% | 100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 89.73% | -- | -- | -- |
| Cash from Investing | 96.49% | 93.48% | 100.00% | -- | -307.14% |
| Total Debt Issued | -- | -- | -- | 607.30% | -- |
| Total Debt Repaid | -268.89% | -4.12% | 6.87% | 1.98% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 98.80% | -- | -- | -- |
| Cash from Financing | -268.89% | -111.73% | -124.45% | 123.78% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 389.40% | -1,478.95% | 206.67% | -12,133.33% | 237.61% |